Spectral Med Stock Performance

EDTXF Stock  USD 0.97  0.01  1.02%   
The entity has a beta of -0.53, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Spectral Med are expected to decrease at a much lower rate. During the bear market, Spectral Med is likely to outperform the market. At this point, Spectral Med has a negative expected return of -0.13%. Please make sure to validate Spectral Med's treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Spectral Med performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Spectral Med has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
Begin Period Cash Flow5.8 M
Total Cashflows From Investing Activities-325 K
  

Spectral Med Relative Risk vs. Return Landscape

If you would invest  108.00  in Spectral Med on November 8, 2025 and sell it today you would lose (13.00) from holding Spectral Med or give up 12.04% of portfolio value over 90 days. Spectral Med is currently producing negative expected returns and takes up 4.145% volatility of returns over 90 trading days. Put another way, 37% of traded pink sheets are less volatile than Spectral, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Spectral Med is expected to under-perform the market. In addition to that, the company is 5.06 times more volatile than its market benchmark. It trades about -0.03 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

Spectral Med Target Price Odds to finish over Current Price

The tendency of Spectral Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.97 90 days 0.97 
about 50.0
Based on a normal probability distribution, the odds of Spectral Med to move above the current price in 90 days from now is about 50.0 (This Spectral Med probability density function shows the probability of Spectral Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Spectral Med has a beta of -0.53 suggesting as returns on the benchmark increase, returns on holding Spectral Med are expected to decrease at a much lower rate. During a bear market, however, Spectral Med is likely to outperform the market. Additionally Spectral Med has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Spectral Med Price Density   
       Price  

Predictive Modules for Spectral Med

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Spectral Med. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Spectral Med's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.050.955.09
Details
Intrinsic
Valuation
LowRealHigh
0.040.814.95
Details
Naive
Forecast
LowNextHigh
0.020.965.11
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.880.961.05
Details

Spectral Med Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Spectral Med is not an exception. The market had few large corrections towards the Spectral Med's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Spectral Med, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Spectral Med within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.1
β
Beta against Dow Jones-0.53
σ
Overall volatility
0.05
Ir
Information ratio -0.05

Spectral Med Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Spectral Med for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Spectral Med can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Spectral Med generated a negative expected return over the last 90 days
Spectral Med has some characteristics of a very speculative penny stock
Spectral Med has high historical volatility and very poor performance
The company reported the revenue of 2.05 M. Net Loss for the year was (8.79 M) with profit before overhead, payroll, taxes, and interest of 1.22 M.
Spectral Med has accumulated about 3.47 M in cash with (8.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Roughly 20.0% of the company shares are held by company insiders

Spectral Med Fundamentals Growth

Spectral Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Spectral Med, and Spectral Med fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spectral Pink Sheet performance.

About Spectral Med Performance

By analyzing Spectral Med's fundamental ratios, stakeholders can gain valuable insights into Spectral Med's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spectral Med has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spectral Med has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada. SPECTRAL MEDICAL operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 31 people.

Things to note about Spectral Med performance evaluation

Checking the ongoing alerts about Spectral Med for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Spectral Med help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Spectral Med generated a negative expected return over the last 90 days
Spectral Med has some characteristics of a very speculative penny stock
Spectral Med has high historical volatility and very poor performance
The company reported the revenue of 2.05 M. Net Loss for the year was (8.79 M) with profit before overhead, payroll, taxes, and interest of 1.22 M.
Spectral Med has accumulated about 3.47 M in cash with (8.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Roughly 20.0% of the company shares are held by company insiders
Evaluating Spectral Med's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Spectral Med's pink sheet performance include:
  • Analyzing Spectral Med's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spectral Med's stock is overvalued or undervalued compared to its peers.
  • Examining Spectral Med's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Spectral Med's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spectral Med's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Spectral Med's pink sheet. These opinions can provide insight into Spectral Med's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Spectral Med's pink sheet performance is not an exact science, and many factors can impact Spectral Med's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Spectral Pink Sheet analysis

When running Spectral Med's price analysis, check to measure Spectral Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spectral Med is operating at the current time. Most of Spectral Med's value examination focuses on studying past and present price action to predict the probability of Spectral Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spectral Med's price. Additionally, you may evaluate how the addition of Spectral Med to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Fundamental Analysis
View fundamental data based on most recent published financial statements
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.